Research ArticleClinical Investigations
Analysis of 177Lu-DOTA-Octreotate Therapy–Induced DNA Damage in Peripheral Blood Lymphocytes of Patients with Neuroendocrine Tumors
Delphine Denoyer, Pavel Lobachevsky, Price Jackson, Mick Thompson, Olga A. Martin and Rodney J. Hicks
Journal of Nuclear Medicine April 2015, 56 (4) 505-511; DOI: https://doi.org/10.2967/jnumed.114.145581
Delphine Denoyer
1Molecular Imaging and Targeted Therapeutics, Translational Research Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia
2Centre for Cellular and Molecular Biology, Deakin University, Burwood, Australia
Pavel Lobachevsky
3Molecular Radiation Biology Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia
4Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia; and
Price Jackson
5Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia.
Mick Thompson
5Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia.
Olga A. Martin
3Molecular Radiation Biology Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia
4Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia; and
5Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia.
Rodney J. Hicks
1Molecular Imaging and Targeted Therapeutics, Translational Research Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia
4Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia; and
5Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia.

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 56, Issue 4
April 1, 2015
Analysis of 177Lu-DOTA-Octreotate Therapy–Induced DNA Damage in Peripheral Blood Lymphocytes of Patients with Neuroendocrine Tumors
Delphine Denoyer, Pavel Lobachevsky, Price Jackson, Mick Thompson, Olga A. Martin, Rodney J. Hicks
Journal of Nuclear Medicine Apr 2015, 56 (4) 505-511; DOI: 10.2967/jnumed.114.145581
Analysis of 177Lu-DOTA-Octreotate Therapy–Induced DNA Damage in Peripheral Blood Lymphocytes of Patients with Neuroendocrine Tumors
Delphine Denoyer, Pavel Lobachevsky, Price Jackson, Mick Thompson, Olga A. Martin, Rodney J. Hicks
Journal of Nuclear Medicine Apr 2015, 56 (4) 505-511; DOI: 10.2967/jnumed.114.145581
Jump to section
Related Articles
Cited By...
- Dosimetric Evaluation of the Effect of Receptor Heterogeneity on the Therapeutic Efficacy of Peptide Receptor Radionuclide Therapy: Correlation with DNA Damage Induction and In Vivo Survival
- Dissimilar DNA Damage to Blood Lymphocytes After 177Lu-Labeled DOTATOC or Prostate-Specific Membrane Antigen Therapy
- Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns?
- Imaging DNA Damage Repair In Vivo After 177Lu-DOTATATE Therapy
- Identification of brain metastasis genes and therapeutic evaluation of histone deacetylase inhibitors in a clinically relevant model of breast cancer brain metastasis
- The Relevance of Dosimetry in Precision Medicine
- Identification of brain metastasis genes and therapeutic evaluation of histone deacetylase inhibitors in a clinically relevant model of breast cancer brain metastasis
- Localized Synchrotron Irradiation of Mouse Skin Induces Persistent Systemic Genotoxic and Immune Responses
- Radiotherapy for Non-Small Cell Lung Cancer Induces DNA Damage Response in Both Irradiated and Out-of-field Normal Tissues
- Myeloid neoplasms after chemotherapy and PRRT: myth and reality
- DNA Damage in Peripheral Blood Lymphocytes of Thyroid Cancer Patients After Radioiodine Therapy
- Radiopeptides for Imaging and Therapy: A Radiant Future
- {gamma}-H2AX Foci in Peripheral Blood Lymphocytes to Quantify Radiation-Induced DNA Damage After 177Lu-DOTA-Octreotate Peptide Receptor Radionuclide Therapy